Since the concept of TfR binding to pass the BBB to treat MPS2 and neuronal ceroid lipofuscinosis (NCL) has been validated in humans56,57, we now extend these findings for neuronopathic GD. This evidence concerns the gene IDS and neuronal ceroid lipofuscinosis.